Etrasimod arginine

精氨酸艾曲莫德

Report date: 2026/05/16 20:00:17
NME

Base Information

Drug NameEtrasimod arginine
Drug Alias NameEtrasimod伊曲莫德Etrasimod L-arginine艾曲莫德Verespiti +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSphingosine 1-Phosphate Receptor 1 modulatorsSphingosine 1-phosphate receptor 4 modulatorsSphingosine 1-phosphate receptor 5 modulators
TargetsSphingosine 1-Phosphate Receptor 1Sphingosine 1-phosphate receptor 4Sphingosine 1-phosphate receptor 5
Therapy Area/IndicationsPyoderma GangrenosumAlopecia AreataEczema +[11] 
Global Approved IndicationsCrohn DiseaseColitis, Ulcerative
Approved Indications in ChinaColitis, Ulcerative
Original Approved Country/TerritoryUnited States
Original Approved Date2023/10/12
Country/TerritoryCzechiaBelgiumBulgaria +[50] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesArena Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesYunding Xinyao Co LtdEverest Medicines LtdEverstar Therapeutics Ltd +[10] 
Inactive CompaniesN/A
Active IndicationsAlopecia AreataDermatitis, AtopicAnemia, Aplastic +[7] 
Inactive IndicationsPyoderma GangrenosumEczemaInflammatory Bowel Diseases +[4] 

Other Information

ATC CodeL04AE
Related LinksWikipediaDrugBankKEGG